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Background and aim: The role of endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) in the diagnosis and staging of lung cancer is still not fully explored. This
prospective study aimed to define the effectiveness of EUS-FNA as an adjunct to computer
tomography (CT) and bronchoscopy in the evaluation of suspected lung cancer in routine
clinical practice.
Methods: Over a period of 20 weeks, the data of 16 consecutive patients suspected of lung
cancer on account of respiratory symptoms, and/or the findings of either a mass or
mediastinal lymph nodes on helical CT, who were referred for evaluation by EUS, were
prospectively collected. Fourteen of these patients underwent sequential bronchoscopy
followed by EUS-FNA in the same setting.
Results: Bronchoscopy was performed in 15 patients, while EUS was performed in all 16
patients. Bronchoscopy diagnosed 9 cases of non-small-cell lung cancer (NSCLC) but was
falsely negative in 3 cases of malignancies, which were all established by EUS-FNA of
mediastinal lymph nodes (2 cases of NSCLC and 1 case of esophageal squamous cell
cancer). EUS-FNA also diagnosed advanced NSCLC in another patient who did not undergo
bronchoscopy, such that eventually 13 patients were diagnosed to have malignancies.
Distant metastases were diagnosed by EUS-FNA in 4 cases of NSCLC (2 cases of left adrenal
gland and 2 cases of pancreatic metastases). Two patients were diagnosed to have
sarcoidosis and 1 patient was diagnosed to have pneumoconiosis eventually.
Conclusions: EUS-FNA is useful as an adjunct to CT and bronchoscopy in the evaluation of
suspected lung cancer.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
0 3558; fax: +65 6781 6202.
gh.com.sg (T.L. Ang).
ARTICLE IN PRESS
T.L. Ang et al.1300Background
Lung cancer is the most common cancer in males with an age-
standardized rate (ASR) of 45per 100,000/year, and the third
most common cancer in females with an ASR of 16.3per
100,000/year, in Singapore. It is also the most frequent cause
of cancer-related mortality both in the world as well as in
Singapore.1 At diagnosis, less than 30% of patients are suitable
for curative surgery because of either advanced tumor stage
or medical comorbidities.2 Obtaining histological confirmation
of the diagnosis of lung cancer, and accurate staging of the
extent of disease, are crucial before planning either curative
surgical resection or palliative radiotherapy or chemotherapy.
In terms of obtaining tissue diagnosis, bronchoscopy is
commonly used, but it may be falsely negative in 30%.3
Radiologically guided percutaneous transthoracic needle
biopsy is another option but it has a risk of pneumothorax of
up to 30%,4 especially for non-peripheral lung lesions.
Mediastinoscopy and open surgical mediastinal staging have
been the standard but are more invasive. Computer tomo-
graphy (CT) though commonly used for preoperative staging,
is known to miss sub-centimeter lymph nodes as well as fall to
accurately detect structural invasion by tumor. Accurate
staging is important both as guide to treatment as well as a
guide to prognosis; the stage-dependent 5 year survival after
the diagnosis of non-small-cell lung cancer (NSCLC) is follows:
I: 46.9%; II: 26.1%; III: 8.4%; IV: 1.6%.5
Endoscopic ultrasound (EUS) is currently available to image
mediastinal lesions with a high degree of accuracy, as well as
to obtain tissue diagnosis with no documented complica-
tions.6 It has been shown to detect malignant mediastinal
lymphadenopathy not shown by CT7,8 and even positron
emission tomography.8 It may also detect occult lesions in the
left adrenal gland,9 left lobe of liver10 and pancreas.11
The role of EUS-guided fine needle aspiration (EUS-FNA) in
obtaining tissue diagnosis of the primary tumor, as well as to
assess the extent of extra-pulmonary intra-thoracic and
extra-thoracic metastases, is still not fully explored. This
prospective study aimed to define the effectiveness of EUS-
FNA as an adjunct to CT and bronchoscopy in the evaluation
of suspected lung cancer in routine clinical practice.
Methods
Patient selection
Over a 20 week period from 20 January 2006 to 9 June 2006,
the data of 16 consecutive patients suspected of lung cancer
on account of respiratory symptoms, and/or the findings of
either a mass or mediastinal lymph nodes on helical CTwho
were referred for evaluation by EUS were prospectively
collected. Fourteen of these patients underwent sequential
bronchoscopy followed by EUS in the same setting, 1 patient
underwent bronchoscopy and EUS on separate sessions and 1
patient underwent EUS without bronchoscopy.
Endoscopic procedures
Bronchoscopy: Fibreoptic bronchoscopy (BF-1T160 or BF-
P160, Olympus, Tokyo, Japan) was performed by a single
pulmonologist (A.T.K.H.) using a transnasal approach.A combination of intravenous midazolam and fentanyl was
used for sedation. Visible endobronchial lesions were
brushed and biopsied and bronchoalveolar lavage was
performed for all cases undergoing bronchoscopy. Trans-
bronchial needle aspiration (TBNA) of subcarinal lymph
nodes was performed blind with a 22-gauge needle (Bard
Endoscopic Technologies, Billerica, MA) if these were
enlarged based on review of the thoracic CT.
EUS and FNA: Diagnostic EUS was performed with a linear-
array echoendoscope (GF-UC160P, Olympus, Tokyo, Japan)
using the Aloka SSD 5000 ultrasound processor (Aloka Co.
Ltd., Tokyo, Japan) by 2 gastroenterologists experienced in
performing EUS (A.T.L.; C.T.S.). A combination of intrave-
nous midazolam and fentanyl was used for conscious
sedation. The echoendoscope was introduced into the
stomach, and screening of the left lobe and central
segments of the liver, celiac axis and left adrenal gland
was routinely performed. When indicated by clinical data,
such as the presence of intra-abdominal lymph nodes on CT,
EUS examination of the pancreas was performed. The
echoendoscope was then withdrawn into the esophagus
and attempts were made to identify any visible mediastinal
lymph nodes, and the location was classified according to
the Mountain/Dresler Regional Nodal Stations for Lung
Cancer Staging.12 For all lymph nodes, notations were made
concerning the dimensions, shape, and echogenicity as well
as edge characteristics. EUS-FNA was performed using a 22-
gauge needle (Echo-1-22 or Echo-3-22, Cook Endoscopy,
Winston-Salem, NC, USA) under Doppler guidance. When
lesions were identified intra-abdominally, FNA of these
lesions were performed first, followed by FNA of the
mediastinal lymph nodes (contralateral nodes first, then
ipsilateral nodes).
On-site cytopathologic assessment
On-site cytopathologic assessment was available to guide
the FNA in 7 cases. The aspirated material was smeared onto
slides, air-dried and stained with Diff-Quik (American
Scientific Products, McGraw Park, Ill) and reviewed by a
cytotechnologist. Additional slides were fixed in 95% ethanol
for formal histopathological review by the cytopathologist.
When on-site cytopathologic assessment was not available,
the endoscopist assessed the cellular adequacy of the
aspirate as previously reported.13
Statistical analysis and ethical considerations
Statistical analysis of the patients’ data and clinical
parameters were expressed as mean and median values
and ranges and proportions. Informed written consent was
obtained from all patients prior to all procedures.
Results
Demographics
Sixteen consecutive patients (13 males, 3 females) were
evaluated by EUS. The median age was 68.5 years (range
46–87). Fourteen out of 15 patients who presented with
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tysis underwent bronchoscopy and EUS-FNA at the same
setting, while 1 patient had the procedures performed on
separate sessions. One patient was referred for EUS
evaluation of intra-abdominal lymph nodes seen on CT after
presenting with abdominal pain and did not undergo
bronchoscopy. In terms of CT findings, 3 patients had
mediastinal lymphadenopathy only, 1 patient had a right
upper lobe mass, 3 patients had right upper lobe masses and
mediastinal lymphadenopathy, 3 patients had right lower
lobe masses and mediastinal lymphadenopathy (of which 2
also had left adrenal masses), 2 patients had right middle
lobe masses and mediastinal lymphadenopathy, 2 patients
had left lower lobe masses and mediastinal lymphadeno-
pathy (as well as intra-abdominal lymphadenopathy in 1
patient), and 2 patients had left upper lobe masses with
mediastinal lymphadenopathy.Bronchoscopy and EUS-FNA
Bronchoscopy was performed in 15 patients and it diagnosed
NSCLC in 9 patients. It was falsely negative for malignancy inTable 1 Results of bronchoscopy and EUS-FNA.
Patient profile Results of bronchoscopy
biopsies and TBNA
1 72 year; male Poorly differentiated SCC
2 50 year; female Mainly bloody aspirate, with
no malignant cells or
granulomas
3 70 year; male Non-small-cell carcinoma
4 87 year; male Non-small-cell carcinoma
5 79 year; male Non-small-cell carcinoma
6 67 year; male Adenocarcinoma
7 46 year; male Non-small-cell carcinoma
8 68 year; male Inflammatory cells
9 73 year; male Non-small-cell carcinoma
10 67 year; male Inflammatory yield with no
malignant cells
11 47 year; male Not performed
12 59 year; male No malignant cells seen
13 59 year; male Moderately differentiated
SCC
14 76 year; male Poorly differentiated SCC
15 69 year; female Granulomatous inflammation
16 83 year; female No malignant cells seen
SCC: squamous cell carcinoma; NSCLC: non-small-cell lung cancer; S3 cases. EUS was performed in 16 patients and EUS-FNA in 15
patients because 1 patient diagnosed with NSCLC by
bronchoscopy did not undergo EUS-FNA due to absence of
visible mediastinal lymph nodes and distant metastases
(Table 1). A cellular aspirate was obtained in all the 15 cases
that underwent EUS-FNA. EUS-FNA of mediastinal lymph
nodes (Figs. 1 and 2) was performed in 14 cases; 1 patient
with mediastinal lymphadenopathy did not undergo
EUS-FNA of the mediastinal lymph nodes after the presence
of left adrenal metastases was confirmed by the on-site
cytotechnologist. EUS-FNA was able to diagnose the 3 cases
of malignancies missed by bronchoscopy (2 cases of NSCLC
and 1 case of esophageal squamous cell cancer with
subcarinal lymph node metastases). In addition, EUS-FNA
confirmed the presence of malignant mediastinal lympha-
denopathy in 9 cases of malignancies (the results of
FNA for 2 cases of NSCLC revealed reactive lymphoid
hyperplasia). It also diagnosed the presence of distant
metastases in 4 cases of NSCLC [2 cases of left adrenal
gland metastases, one of which was not seen on CT (Fig. 3),
and 2 cases of pancreatic metastases, one of which
was not seen on CT]. Three patients who underwent
both bronchoscopy and EUS-FNA of mediastinal lymphResults of EUS-FNA Diagnosis
SCC metastatic to SC and AP
LN
NSCLC
Granulomatous inflammation
in mediastinal LN
Sarcoidosis
NSCLC metastatic to pancreas NSCLC
NSCLC metastatic to SC and
AP LN
NSCLC
NSCLC metastatic to left
adrenal gland
NSCLC
Adenocarcinoma metastatic
to left adrenal gland
NSCLC
Not performed NSCLC
FNA of SC/AP LN: reactive
lymphoid hyperplasia
Pneumoconiosis
FNA of SC/AP LN: reactive
lymphoid hyperplasia
NSCLC
NSCLC metastatic to SC LN NSCLC
NSCLC metastatic to pancreas NSCLC
NSCLC metastatic to SC and
AP LN
NSCLC
FNA of SC LN: reactive
lymphoid hyperplasia
NSCLC
SCC metastatic to SC LN NSCLC
FNA of SC LN: granulomatous
inflammation
Sarcoidosis
Esophageal SCC metastatic to
SC LN
Esophageal SCC
C: subcarina; AP: aortopulmonary window; LN: lymph nodes.
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Figure 1 EUS-FNA of malignant lymph nodes in the subcarinal
region: (A) left atrium; (B) right pulmonary artery; and (C) FNA
of subcarinal lymph node.
Figure 2 EUS-FNA of malignant lymph nodes in the aortopul-
monary window: (A) right pulmonary artery; (B) aorta; and
(C) FNA of malignant lymph node.
Figure 3 FNA of a left adrenal gland metastasis from lung
cancer: (A) FNA of mass in body of left adrenal gland.
T.L. Ang et al.1302nodes were eventually diagnosed to have pneumoconiosis
(1) and sarcoidosis (2), respectively. The former underwent
a CT guided core biopsy of the lung mass after both
bronchoscopy and EUS-FNA revealed only inflammatory
cells. The latter two had granulomatous inflammation seen
on EUS-FNA.
Clinical impact of EUS-FNA
EUS-FNA had a significant impact in terms of both tumor
diagnosis and tumor staging. The diagnosis of cancer
in 4 out of 13 patients was only made by EUS-FNA. EUS-
FNA also confirmed the presence of distant metastases
in 4 out of 13 patients, and the presence of malignant
mediastinal nodal involvement in 9 out of 11 patients
with malignancies who underwent mediastinal FNA
(2 patients had reactive lymphoid hyperplasia). One
NSCLC patient with absence of malignant mediastinal lymph
nodes on EUS was found to have a malignant right apical
lymph node at surgery. No procedural complications
occurred.
Discussion
Accurate tumor diagnosis and staging is crucial for appro-
priate patient counseling and management. Among patients
with lung cancer, a large proportion may present with
extensive mediastinal lymph node metastases or distant
metastases and are hence not suitable for surgery. Our
results show that EUS-FNA is useful and effective as an
adjunct to CT and bronchoscopy in the evaluation of
mediastinal lymphadenoapthy, diagnosis and staging of lung
cancer in routine clinical practice. The diagnosis of cancer
was made only by EUS-FNA in 31% of cases, and distant
metastases, i.e. stage IV disease, was confirmed in 31% of
cases by EUS-FNA.
The clinical utility of EUS-FNA resides in its ability to
detect and biopsy lesions that may not be visualized by CT
without any complications. For instance, it has been shown
that EUS can demonstrate advanced mediastinal disease in
61% of patients without CT suspicion of mediastinal lymph
nodes14; another study showed that EUS precluded unne-
cessary surgery in 12% of NSCLC without CT evidence of
mediastinal lymph nodes based on the presence of stage IIIA
or IIIB disease detected by EUS-FNA.15 In addition, EUS-FNA
has also been shown to be very useful in terms of obtaining
tissues for the purpose of achieving histological diagnoses.
EUS-FNA of mediastinal masses in absence of known lung
malignancy has been shown to achieve an accurate diagnosis
in 94%, of which 45% were malignancies.16 In another study,
EUS-FNA was useful in confirming the diagnosis of advanced
lung cancer, with a correct diagnosis made in 86%, including
24% with prior failed attempts in obtaining histological
diagnoses.17
In terms of clinical outcome studies, preoperative EUS-
FNA for patients with mediastinal lymph nodes and lung
cancer being scheduled for surgical staging (i.e. mediastino-
scopy or exploratory thoracotomy) has been shown to
prevent 70% of scheduled surgical procedures because of
the demonstration of lymph node metastases and tumor
invasion (69%), or benign diagnoses (1%).18 Preliminary
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either routine preoperative EUS-FNA for all patients vs.
selective EUS-FNA showed that futile thoracotomies were
reduced from 25% to 9%. These results are important
because published data have shown that up to 45% of
operations with curative intent for NSCLC were futile
because the stage of disease was more advanced than
expected preoperatively.19
There are limitations to the use of EUS in lung cancer.
Firstly, echo features by themselves are not sufficient to
differentiate benign from malignant lymph nodes. EUS
features suggestive of malignant nodes are size greater
than 1 cm, round or oval shape, diffusely hypoechoic and
sharp edges; in the presence of 3 or 4 classic features, the
sensitivity was 78% and specificity 81%. This underscores the
importance of EUS-FNA, which is 100% specific, rather than
EUS per se.20 Secondly, certain parts of the mediastinum
may not be that well accessed by EUS-FNA. EUS cannot
access the region anterior to trachea and main bronchi, as
well as the right paratracheal region, due to the intervening
air. Thus mediastinoscopy, although it is more invasive, still
has a role in this area.21 In addition, real-time endobronchial
ultrasound-guided transbronchial needle aspiration (real-
time EBUS-TBNA), which has been recently introduced,
replaces the blind nature of TBNA in obtaining tissue
samples from the anterior mediastinum and may have a
role as a less invasive alternative to mediastinoscopy in this
respect. When EBUS-TBNA is combined with EUS-FNA, the
need for more invasive tests can be potentially reduced
since both the anterior (by EBUS-TBNA) and posterior (by
EUS-FNA) mediastinum can be accessed. A recent prelimin-
ary study showed that using such a combined approach, the
accuracy rate for the diagnosis of mediastinal cancer was
100% (95% CI: 83–100%).22
Although our sample size was relatively small at 16
patients, we believe that our results are sufficient to show
the effectiveness of EUS-FNA in routine clinical practice.
Only 1 patient in our study underwent surgery eventually so
that surgical histopathological correlation could be made. In
this patient, EUS did not show any mediastinal lymph nodes
and hence FNA was not performed; however, the surgical
specimen revealed a malignant right apical lymph node,
thus reiterating the earlier point concerning the limitation
of EUS in accessing lymph nodes in this region. For the
patients with malignant cytology from EUS-FNA, although
there was no surgical correlation, the results are unlikely to
be false positives since the FNA needle did not traverse any
intervening areas of malignancy when tissue specimens were
obtained. However, this study is not able to state categori-
cally whether the two EUS-FNA results, which showed
reactive lymph nodes, were true results or false
negatives from sampling errors. When available, on-site
cytopathologic assessment could be useful in guiding the
number of passes required for adequate tissue materials.
Unfortunately, this was not feasible in every case due to
logistical difficulties. Nonetheless, even when based
simply on the assessment of the endosonographer,13 an
adequate cellular aspirate could be obtained in all
cases.
We conclude that EUS-FNA is useful as an adjunct to CT
and bronchoscopy in the evaluation of suspected lung cancer
in routine clinical practice.References
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